About the Charleston Conference on Alzheimer's Disease (CCAD)

About CCAD

The Charleston Conference on Alzheimer’s Disease (CCAD) originated in 2013 to develop new methods to better understand Alzheimer’s Disease (AD). CCAD invests in early career researchers and provides a platform for competitive innovation in this field.

Three $50,000 New Vision awards are given to the researchers with the top paramount ideas. The award will help develop their concepts and mature the research for future government funding.

On average, CCAD receives fifty applicants from which the top fifteen are selected to attend the three-day, all expenses paid conference. The CCAD board, comprised of leading scientific research professionals, will choose the top three that represent innovation and challenge the current paradigm of Alzheimer's research.

Since our beginning, CCAD has awarded over $1 million in research grants to early career investigators studying Alzheimer’s Disease. Our $50,000 New Vision Awards propel young investigators forward maturing their research with the intention of acquiring future National Institutes of Health (NIH) funding.

Collectively, the CCAD award recipients have secured $21 million in NIH funding since attending the conference, while attendees went on to receive $15 million. Recipients of the New Vision Award received 30% more funding in the year's post-conference than those who attended. These numbers are reflected in the graph, which shows the impact of early-career funding.

CCAD alumni share their experiences below:

“Getting the award has influenced my Alzheimer's disease colleagues' interest in involving me in their ongoing and future developments. It took me from being an aspiring AD researcher to having some credibility!”

“I met some fantastic people and got to know the chairing committee very well, which was fantastic. Overall, a great experience that gave me a real insight into the granting process (invaluable).”